Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 3 , Pages 266-270 , May 2008

Vesical vs. extra-vesical patterns of recurrence after the treatment of urothelial upper tract tumors

  • Sergey Shikanov, M.D.

      Affiliations

    • Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    • ,
  • Amos Shapiro, M.D.

      Affiliations

    • Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    • ,
  • Lea Baer, M.D.

      Affiliations

    • Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    • ,
  • Ezekiel H. Landau, M.D.

      Affiliations

    • Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    • ,
  • Ran Katz, M.D.

      Affiliations

    • Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    • ,
  • Ofer N. Gofrit, M.D., Ph.D

      Affiliations

    • Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972-2-6776874; fax: +972-2-6430929.

Received 8 February 2007 ,Revised 15 April 2007 ,Accepted 16 April 2007.

References 

  1. Raman JD, Ng CK, Boorjian SA, et al. Bladder cancer after managing upper urinary tract transitional cell carcinoma: Predictive factors and pathology. BJU Int. 2005;96:1031–1035
  2. Koga F, Nagamatsu H, Ishimaru H, et al. Risk factors for the development of bladder transitional cell carcinoma following surgery for transitional cell carcinoma of the upper urinary tract. Urol Int. 2001;67:135–141
  3. Hall MC, Womack S, Sagalowsky AI, et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: A 30-year experience in 252 patients. Urology. 1998;52:594–601
  4. Matsui Y, Utsunomiya N, Ichioka K, et al. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology. 2005;65:279–283
  5. Hisataki T, Miyao N, Masumori N, et al. Risk factors for the development of bladder cancer after upper tract urothelial cancer. Urology. 2000;55:663–667
  6. Kang CH, Yu TJ, Hsieh HH, et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer. 2003;98:1620–1626
  7. Cozad SC, Smalley SR, Austenfeld M, et al. Transitional cell carcinoma of the renal pelvis or ureter: Patterns of failure. Urology. 1995;46:796–800
  8. Bamias A, Deliveliotis C, Fountzilas G, et al. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: A study by the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:2150–2154
  9. Lerner SE, Blute ML, Richardson RL, et al. Platinum-based chemotherapy for advanced transitional cell carcinoma of the upper urinary tract. Mayo Clin Proc. 1996;71:945–950
  10. Redman BG, Smith DC, Flaherty L, et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol. 1998;16:1844–1848
  11. Igawa M, Ohkuchi T, Ueki T, et al. Usefulness and limitations of methotrexate, vinblastine, doxorubicin, and cisplatin for the treatment of advanced urothelial cancer. J Urol. 1990;144:662–665
  12. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–866
  13. Fechner G, Siener R, Reimann M, et al. German Association Of Urologic Oncology (AUO) Bladder Cancer Study Group Randomized phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract. 2006;60:27–31
  14. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol. 2005;174:14–20
  15. Canfield SE, Dinney CP, Droller MJ. Surveillance and management of recurrence for upper tract transitional cell carcinoma. Urol Clin North Am. 2003;30:791–802
  16. Kwiatowski DJ, Harpole DH, Godleski JU International Union against Cancer (IUCC). Urinary bladder. In:  Sobin LH,  Wittekind CH editor. TNM classification of Malignant Tumors. New York: Wiley-Liss; 1997;p. 187–190
  17. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder (Bladder Consensus Conference Committee). Am J Surg Pathol. 1998;22:1435–1448
  18. Shipley WU, Kaufman DS, Heney NM, et al. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. J Urol. 1999;162:445–450
  19. Herr HW, Bajorin DF, Scher H. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: Ten-year outcome. J Clin Oncol. 1998;16:1298–1301
  20. Kurth KH, Denis L, Bouffioux C, et al. Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer. 1995;31A:1840–1846
  21. Jabbour ME, Smith AD. Primary percutaneous approach to upper urinary tract transitional cell carcinoma. Urol Clin North Am. 2000;16:483–487
  22. Canfield SE, Dinney CP, Droller MJ. Surveillance and management of recurrence for upper tract transitional cell carcinoma. Urol Clin North Am. 2003;30:791–802
  23. Duggan BJ, Gray SB, McKnight JJ, et al. Oligoclonality in bladder cancer: The implication for molecular therapies. J Urol. 2004;171:419–425
  24. Holmang S, Johansson SL. Bilateral metachronous ureteral and renal pelvic carcinomas: Incidence, clinical presentation, histopathology, treatment, and outcome. J Urol. 2006;175:69–72

PII: S1078-1439(07)00128-7

doi: 10.1016/j.urolonc.2007.04.007

Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 3 , Pages 266-270 , May 2008

Article Tools

* Image Usage & Resolution